Boule Diagnostics AB (publ) acquires technologies for the next generation product platform

Boule has acquired technologies that will be used for the next generation platform for the 5-part segment

Through this acquisition Boule will get access to new technologies in the field of laser optics that will be adapted to Boule’s requirements and be used in combination with internally developed technologies for the next generation product platform. The acquisition will reduce time to market for the next product launch in the fast growing 5-part segment, and simultaneously reduce development cost and risk.

The acquisition is made through Boule’s subsidiary Boule Medical AB and the seller is Drew Scientific, Inc. The purchase price is USD 3 million, out of which USD 750,000 will be paid upon completion of the technology transfer, expected to occur within twelve (12) weeks.

The acquisition is not expected to have an impact on earnings per share in the current fiscal year.

”Through this acquisition Boule will get immediate access to new technologies that will be used for the next generation platform, and we will reduce time to market and strengthen our product portfolio in the fast growing 5-part segment. This is in line with our previously communicated strategy to develop new product platforms and broaden the product portfolio through partnerships and acquisitions” says Fredrik Dalborg, CEO and President, Boule Diagnostics.

For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 70-558 51 05
Christina Rubenhag, CFO Boule Diagnostics AB, phone +46 70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CET on April 19, 2018.

Release